Positive preliminary response from FDA regarding novel proteinuria endpoint

 

NACI’s clinical trial outcomes core has developed a novel data-driven candidate FSGS proteinuria endpoint with a positive reception by members of the FDA’s Cardiorenal Division. This work, led by Jonathan Troost, PhD, was presented at the American Society of Nephrology’s 2016 Annual Meeting.  The presentation can be viewed here.